nivolumabipilimumabpembrolizumabiSCIB1+SCIB1Sheffield Teaching Hospital NHS TrustUniversity College London HospitalNottingham Hospitals University TrustSouthampton General Hospital
…hort 1 has 43 patients all with HLA A2 receiving ipilimumab and nivolumab with 10 doses of intra-muscular SCIB1 over 24-months. Cohort 3 …